• IMV, Wistar Institute Partner to Develop T-cell Immunotherapy Against Cancers with BRAF Mutations
  • Collaborators Aim to Identify OC Patients Likely to Benefit from New Combo Therapy
  • TCR2 Therapeutics, National Cancer Institute Team Up to Develop TC-210 Immunotherapy
  • Activities Underway to Mark Ovarian Cancer Awareness Month
  • Assay Shows Potential in Predicting Ovarian Cancer Response to Chemotherapy
  • Ampligen Combo Safe, Effective in Treating Recurrent Ovarian Cancer, Phase 1 Study Shows
  • ‘Don’t Eat Me’ Signal CD24 May Be Promising Therapeutic Target for Ovarian and Breast Cancers, Study Says
  • Research into Tumor Suppressor P53 in Ovarian Cancer Receives $1.8M NIH Grant
  • Expert Discusses Celsion’s Ovarian Cancer Immunotherapy GEN-1; Phase 1/2 Trial Still Enrolling
  • Rubraca Conditionally Rejected for Use on NHS England for Recurrent Ovarian Cancer
  • Lynparza-Avastin Combo Cuts Risk of Disease Progression, Death in Advanced OC, Phase 3 Trial Shows
  • Honoring its Co-Founder’s Legacy, Newk’s Cares Kicks Off 6th Annual Ovarian Cancer Campaign